Latikafusp

CAS No. 2552814-07-8

Latikafusp( —— )

Catalog No. M36804 CAS No. 2552814-07-8

Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 818 Get Quote
5MG 1311 Get Quote
10MG 1596 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Latikafusp
  • Note
    Research use only, not for human use.
  • Brief Description
    Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.
  • Description
    Latikafusp (AMG 256) is a bifunctional fusion protein comprising a PD-1-targeting antibody and IL-21 mutein designed to deliver IL-21 pathway stimulation to PD-1+ cells. Latikafusp is designed to prime and extend the activity of cytotoxic and memory T cells and induce anti-tumor immunity. Latikafusp has the potential for solid tumors research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    PD-1/PD-L1
  • Recptor
    PD-1/PD-L1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2552814-07-8
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Greg Durm, et al. Abstract CT205: Design and rationale of a phase 1 study evaluating AMG 256, a novel, targeted, PD-1 antibody x IL-21 mutein bifunctional fusion protein, in patients with advanced solid tumors. Clin Cancer Res. 2022 Apr 1;28(7):1294-1301. ?
molnova catalog
related products
  • Evixapodlin

    Evixapodlin (PD-1/PD-L1-IN 7) is a human PD-1/PD-L1 protein/protein interaction inhibitor (IC50: 0.213).Evixapodlin has anticancer and antiviral activities.

  • AUNP-12

    AUNP-12 (Aurigene-012) is a PD-1 inhibitor peptide.

  • PD-1/PD-L1-IN-10

    PD-1/PD-L1-IN-10 is an orally active?PD-1/PD-L1?inhibitor (IC50?of 2.7 nM) with potent anticancer efficacy.